Professor Huilai Zhang : Diligently Striving to Improve Survival Time and Quality of Life for Lymphoma Patients in China | 2024 CSCO Hematology

Professor Huilai Zhang : Diligently Striving to Improve Survival Time and Quality of Life for Lymphoma Patients in China | 2024 CSCO Hematology

2024.03.06
Lymphoma is one of the fastest-growing malignant tumors worldwide, and the incidence rate in China has been gradually increasing in recent years, posing a serious threat to the health of the population. From January 26 to 28, 2024, the "Work Conference of the Leukemia Committee, Lymphoma Committee, and Myeloma Preparatory Committee of the Chinese Society of Clinical Oncology (CSCO) and the 2024 CSCO Academic Conference on Hematology, Lymphoma, and Myeloma Diseases" was successfully held in Haikou. Professor Huilai Zhang from Tianjin Medical University Cancer Institute and Hospital shared insights at the conference on the survival status and diagnosis and treatment strategies for patients with indolent lymphoma, frontline treatment strategies for mantle cell lymphoma, and research progress on immunosuppressants. Following the conference, Oncology Frontier - Hematology Frontier invited Professor Zhang for an in-depth sharing session.
Professor Shuye Wang: Emphasizing early diagnosis and treatment of systemic amyloidosis to improve patient cure rates | 2024 CSCO Hematology Academic

Professor Shuye Wang: Emphasizing early diagnosis and treatment of systemic amyloidosis to improve patient cure rates | 2024 CSCO Hematology Academic

2024.03.06
Due to its low incidence and diverse clinical manifestations, patients with AL amyloidosis are often misdiagnosed or underdiagnosed, resulting in insufficient treatment. From January 26th to 28th, 2024, the "China Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, and the 2024 CSCO Hematology, Lymphoma, and Myeloma Disease Academic Conference" was successfully held in Haikou. During the conference, Professor Shuye Wang from the First Affiliated Hospital of Harbin Medical University shared insights with Oncology Frontier - Hematology Frontier on the current status of diagnosis and treatment of systemic amyloidosis, perspectives on early diagnosis, and the future research plans of his team.
Prof. Jun Ma: Key Components for Hematologic Malignancies’ Future – Medical Administration, Pharmaceuticals, and Doctor-Patient Relations | 2024 CSCO

Prof. Jun Ma: Key Components for Hematologic Malignancies’ Future – Medical Administration, Pharmaceuticals, and Doctor-Patient Relations | 2024 CSCO

2024.03.05
Amidst the waves and scenic beauty, from January 26th to 28th, the "China Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, and the 2024 CSCO Hematology, Lymphoma, and Myeloma Disease Academic Conference" was grandly held in the beautiful city of Haikou. Renowned experts and scholars from both domestic and international arenas gathered to share and exchange important research findings in the fields of leukemia, lymphoma, and myeloma over the past year. They also delved into in-depth discussions on hot topics in diagnosis and treatment. Oncology Frontier - Hematology Frontier had the privilege of interviewing Professor Jun Ma, the executive chairman of this conference and director of the Harbin Institute of Hematological Tumors. He elaborated on the highlights and exciting aspects of the conference, shared insights on the significance of establishing standardized lymphoma diagnosis and treatment centers, and highlighted the working priorities of the 2024 CSCO Leukemia and Lymphoma Expert Committees.
Professor Aichun Liu: Stratified Treatment and Novel Drugs Resurrect Hope for Relapsed/Refractory B-Cell Lymphoma at the 2024 CSCO Hematology

Professor Aichun Liu: Stratified Treatment and Novel Drugs Resurrect Hope for Relapsed/Refractory B-Cell Lymphoma at the 2024 CSCO Hematology

2024.03.05
In the era of medical innovation, various targeted and immune drugs are emerging, leading to breakthroughs in lymphoma treatment. From January 26th to 28th, 2024, the "Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, as well as the 2024 CSCO Hematology and Lymphoma, and Myeloma Disease Academic Conference" was grandly held in the beautiful city of Haikou. At the conference, experts of all ages from both domestic and international arenas engaged in discussions and exchanges on the latest developments and hot topics in lymphoma diagnosis and treatment. "Oncology Frontier - Hematology Frontier" had the privilege to interview Professor Aichun Liu, Director of the Department of Hematology and Lymphoma at Harbin Medical University Cancer Hospital, regarding his perspectives and opinions on the overall treatment strategy for relapsed/refractory B-cell lymphoma, as well as sharing his team's research plans and management experiences in lymphoma.